HC Wainwright Weighs in on Tourmaline Bio Q2 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Tourmaline Bio in a research report issued on Monday, May 5th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of ($0.94) for the quarter. HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Tourmaline Bio's FY2026 earnings at ($3.79) EPS.

Other analysts have also issued research reports about the stock. Lifesci Capital began coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They set an "outperform" rating and a $58.00 target price on the stock. Chardan Capital reiterated a "buy" rating and issued a $70.00 price objective on shares of Tourmaline Bio in a report on Monday, May 5th. Finally, Wedbush raised their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Friday, March 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $49.33.

Tourmaline Bio Stock Down 4.1 %

Shares of NASDAQ TRML traded down $0.65 during mid-day trading on Tuesday, hitting $15.09. 287,554 shares of the company were exchanged, compared to its average volume of 271,307. The stock has a 50 day simple moving average of $15.49 and a 200-day simple moving average of $18.71. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79. The firm has a market cap of $387.59 million, a price-to-earnings ratio of -5.35 and a beta of 2.11.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.02.

Institutional Trading of Tourmaline Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brooklyn Investment Group acquired a new position in shares of Tourmaline Bio in the 4th quarter valued at approximately $32,000. Tower Research Capital LLC TRC raised its stake in Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after buying an additional 1,232 shares during the period. KLP Kapitalforvaltning AS bought a new position in Tourmaline Bio during the fourth quarter worth $47,000. Virtus ETF Advisers LLC acquired a new stake in Tourmaline Bio during the fourth quarter worth approximately $64,000. Finally, GAMMA Investing LLC grew its holdings in Tourmaline Bio by 4,481.7% in the 1st quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock valued at $114,000 after buying an additional 7,350 shares in the last quarter. 91.89% of the stock is currently owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.